CONTENTS

CEO Letter ........................................................................................................................................................................... 2
Highlights of 2019 ........................................................................................................................................................................ 4
Advancing Treatment Options ......................................................................................................................................................... 9
Financials ..................................................................................................................................................................................... 11
Leadership .................................................................................................................................................................................... 12
Acknowledgement ....................................................................................................................................................................... 10
Industry Partners ........................................................................................................................................................................... 13
Donor Recognition ....................................................................................................................................................................... 14
Dear ARC Supporter,

Another year, another big step forward for Amyloidosis! Adding to the two drugs approved to treat hereditary ATTR amyloidosis, we saw the approval of tafamidis, (vyndaquel™) the first drug to be approved to treat Cardiac ATTR. We have also seen an increase in the number of pharmaceutical companies engaged in the amyloidosis space. We are proud of the patient focused role ARC has played in accelerating the development of new and innovative treatments for amyloidosis that has led to the approval of treatments, with more on the horizon. We will continue to relentlessly push forward in new areas with the goals of making a significant contribution to increasing survival in all types of amyloidosis and measurably improving patients’ quality of life.

Our focus on patients means that ARC is there for every patient, at each step of their amyloidosis journey, from suspicion of a diagnosis, through finding the best available care, to identifying clinical trial opportunities, and providing education, support and tools helping patients live the best life they can. We are continually expanding our services and programs for patients as well as physicians.
As we grow our care initiatives, we remain committed to **advancing research**, and as a patient-founded organization, patients’ needs are the driver for all that we do in our own work, as well as **driving collaborations** we have built among pharmaceutical companies, researchers, clinicians, payers and regulatory bodies. This was particularly evident with the formation of our Public Private Partnership with the Food and Drug Administration (FDA) and the launch of the Amyloidosis Forum, with the inaugural meeting at the FDA campus in Bethesda, Maryland.

The highlights in this report are a direct result of the collaboration and hard work of the entire community-affected individuals, researchers, pharmaceutical companies, and regulators. **As a patient-founded organization, we know how urgent these goals are. We run our business with the same efficiency that we expect of our partners. We consistently outperform our peers in fiscal responsibility, accountability, and transparency.**

We are so grateful for your continued partnership and support. Together we can and will change the future for all those impacted by amyloidosis.

Sincerely,

Isabelle Lousada
HIGHLIGHTS OF 2019

It is our vision that every patient receives a timely diagnosis and has what they need to treat their amyloidosis.

Accelerating Drug Development

Amyloidosis Forum

ARC and the FDA combined forces creating a Public Private Partnership in the form of the ARC run Amyloidosis Forum, to bring a wide group of stakeholders together to identify and address the barriers that exist in drug development with a particular focus on AL amyloidosis. The Forum was launched in 2019 and has made significant strides to bring this rare disease community together to address the barriers in AL amyloidosis drug development.

Since the initial meeting was held in the Great Hall at the FDA, the Forum has grown from strength to strength and garnered international collaboration from disease experts and regulators alike, and expanded to include EMA and MHRA.

The Forum has formed a number of working groups and convened meetings to focus on key priorities that were identified in the initial Amyloidosis Forum meeting. These priorities include:

» Novel trial design and endpoint development
» Natural history
» Role of Imaging to assess burden of disease/response to therapy
» Disease specific patient reported outcome measures
**Improving Care**

**Masterclass**

For physicians specifically, we have developed the Amyloidosis Masterclass, a Continuing Medical Education (CME) program. The Masterclass is an interactive, educational event where attendees learn about amyloidosis care, the value of multidisciplinary teams, how to build an amyloidosis program to best support patients and connect with experts in the field. These conferences are open to all medical specialties but are primarily targeted to practicing physicians who most commonly see and treat amyloidosis patients.

**Pathway to Diagnosis**

As far too many patients know from firsthand experience, amyloidosis is challenging to diagnose. Far too many patients experience significant and potentially life-threatening delays before attaining an accurate diagnosis. ARC spearheaded an initiative to convene international amyloidosis experts across all disciplines to develop consensus guidelines. These have resulted in the publication of guidelines for neurologists, cardiologists and general practitioners on the suspicion and diagnosis of ATTR amyloidosis.

**Putting Patients at the Center of Research**

**ATTR PRO**

ARC has initiated development of an ATTR PRO (Patient Reported Outcomes) measurement tool to be used to understand and measure the impact of the disease on patients from the patient’s perspective. This tool will measure what matters most to patients with ATTR amyloidosis, such as how the disease and/or treatment impact their daily lives, physical functioning, and mental health status. It will allow physicians to monitor patients’ progress and can be incorporated into clinical trials as well as daily care for patients.
Access to Treatments

Regulatory approval is an important step to delivering new treatments for patients, but it is not the final step. Our mission is to ensure that all patients have access to treatments, and our Market Access program has been working on just that.

ARC conducted a patient preference study to generate data that would address the value of novel treatments to the ATTR community. This data was shared with the community along with an ARC Health Technology Assessment toolkit, which we developed to provide a step-by-step guide, along with case studies. It is intended to give information about how treatments are evaluated and approved for use in the various member state healthcare systems and to guide patients and patient groups on how they can participate in the process to ensure those treatments that are developed for their type of amyloidosis can be made available in their countries.

Patient Programs

ARC conducted a patient survey to evaluate patient experiences. The majority of patients reported feeling overwhelmed when receiving their diagnosis, and only a small percent were given written information or guided to resources to help them come to terms with their diagnosis and learn about their disease. In complex, rare diseases like amyloidosis, patients who are well informed are empowered to be active partners with their healthcare providers to make treatment and care decisions that can greatly improve their quality of life. To support patients throughout their amyloidosis journey ARC has developed the following:

MAP

The My Amyloidosis Pathfinder (MAP) helps patients evaluate and navigate finding treatment centers, and provides valuable information about clinical trials and research opportunities. With over 2,000 patients engaged and
regularly using MAP, this tool has become an important way to keep the community informed about research opportunities and accelerate enrollment in clinical trials. Our wonderful support team speak to patients daily and we have seen a significant increase in the number of calls we receive.

**ARC Talks**

Our webinar series, ARC Talks, delves into a broad range of topics that impact patients, from clinical trials, to treatment options, to managing disease symptoms as well as treatment side effects.

With a rapidly changing treatment landscape, we pride ourselves on having the latest information in a variety of easily understandable formats so that all patients have access to information, and support.
The 2019 amyloidosis drug pipeline reflects the amyloidosis community’s progress in research.

<table>
<thead>
<tr>
<th>Company/Drug Name</th>
<th>Pre-Clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Commercial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alnylam - Onpattro hATTR-PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Akcea - Tegsedi hATTR-PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer - Vyndaqel/Vyndamax ATTR-CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janssen - Darzalex AL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eidos - AG10 ATTR-CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alnylam - Vitrusiran ATTR-PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alnylam- Patisiran ATTR-CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alnylam - Vitrusiran ATTR -CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKCEA-TTR-LRxATTR- PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKCEA-TTR-LRx ATTR-CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caelum - Cael-101 (11-1F4) AL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prothena - PRX004 ATTR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intellia - CRISPR ATTR-PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
We would like to acknowledge and thank the amyloidosis research community who were involved throughout the development of the Amyloidosis Research Strategy Roadmap.

These include all who attended the 2018 Research Strategy Roundtable meeting to set the prioritization of key themes, from which ARC’s 2019 priorities were derived.

We would also like to thank each and every patient who has taken part in a clinical trial or other forms of research. We recognize there is no such thing as an easy diagnosis and journey with amyloidosis, and research would not be possible without patients’ involvement and the support of caregivers, families, and friends.

We are grateful to all the different stakeholders that have collaborated with ARC, including amyloidosis researchers and clinicians, patients, and patient foundations, pharmaceutical companies, and regulatory bodies, who together play such an important role in bringing new discoveries from lab benches to patients’ bedsides.

THANK YOU
FINANCIALS

ARC 2019 Statement of Activities

<table>
<thead>
<tr>
<th>Support and Revenue</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$1,602,333</td>
</tr>
<tr>
<td>In-kind contribution</td>
<td>9,300</td>
</tr>
<tr>
<td>Interest</td>
<td>857</td>
</tr>
<tr>
<td>Total Support and Revenue</td>
<td>1,706,598</td>
</tr>
</tbody>
</table>

Expenses

<table>
<thead>
<tr>
<th>Programs</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research/Awareness/Education</td>
<td>1,057,161</td>
</tr>
</tbody>
</table>

Supporting Services

<table>
<thead>
<tr>
<th>Administrative</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>184,706</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>1,337,569</td>
</tr>
</tbody>
</table>

Change in net assets

<table>
<thead>
<tr>
<th>Net assets, beginning of year</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Net assets, end of year</td>
<td>1,094,804</td>
</tr>
<tr>
<td>($369,229)</td>
<td></td>
</tr>
</tbody>
</table>

* The amounts are derived from the audited financial statements.

The full audit is available upon request.
LEADERSHIP

The ARC board and steering committees are comprised of a diverse group of exceptional individuals dedicated to the ARC mission. Together with the ARC staff, they identify areas of opportunity to inform our programs.

**Leadership**

Isabelle Lousada, **PRESIDENT & CEO**

Lincoln, MA

Giampaolo Merlini, MD, **BOARD CO-CHAIR**

University of Pavia, Italy

Raymond Comenzo, **BOARD CO-CHAIR**

Tufts Medical Center, Boston, MA

Dena Heath, **SECRETARY**

Walnut Creek, CA

Jason Shore, **TREASURER**

Newton, MA

Sarah Cairns-Smith, **DIRECTOR**

Lincoln, MA

**2019 Board**

Isabelle Lousada, **PRESIDENT & CEO**

Lincoln, MA

Giampaolo Merlini, MD, **BOARD CO-CHAIR**

University of Pavia, Italy

Raymond Comenzo, **BOARD CO-CHAIR**

Tufts Medical Center, Boston, MA

Dena Heath, **SECRETARY**

Walnut Creek, CA

Jason Shore, **TREASURER**

Newton, MA

Sarah Cairns-Smith, **DIRECTOR**

Lincoln, MA

**2019 Steering Committee**

Raymond Comenzo, MD

Tufts Medical Center

Mathew Maurer, MD

New York-Presbyterian Hospital/Columbia University Medical Center

Angela Dispenzieri, MD

Mayo Clinic

Giampaolo Merlini, MD

University of Pavia

Jeffery Kelly, PhD

The Scripps Research Institute

Vaishali Sanchorawala, MD

Boston Medical Center

Eric Low, OBE

Chairman, Amyloidosis Research Consortium-UK

Ashutosh Wechalekar, MD

Royal Free Hospital

**Patient Advisory Board**

Dena Heath

Walnut Creek, CA

Eric Eckerstrom

Fiddletown, CA

Nancy Verel

Aurora, OH

Dawn Gimbel-Myers

Castro Valley, CA

David Antonaitis

Endicott, NY
DONOR RECOGNITION

Henry Adams
Greg Adams
Pam Agnew
Donna Albin
Ishrath Ali
Sima Rozen Alper
Christine Alvisio
Chris Alviso
Richard Andaya
James Anderson
Lisa Anderson Gavin
Stuart Angert
Jeanne Annino
Despina Anthemides
David Antonaitis
Courtney Arbour
Ryan Arcuri
Jamie Arigropoulos
Stavros Avgoustides
Linda Ayoub
Megan Baierlein
Jane Baird
John Baker
Harold Banks
Chris Barberich
Christine Barkdoll
Michael Barres
Elaine Baselice
Jana Beck
Tori Beck
Joe Becker
David Bednarczyk
Mary Behling
B Belgrave
Bobbi Benjamin
Marina Ramirez-Alvarado Berglund
Cindy Biehl
Teresa Bitancurt
Landy Blackwell
Libby Blaney
Deborah Boedicker
David Boome
David Bottini
Jessica Bourgeois
Coco Brandon
James Bridgeman
Bob Brodie
Todd Brown
Ryan Brown
Marian Brubaker
Grazyna Brylowska
Maria Buenavista
Jeremy Burris
Jill Burt
Brigid Burzanko
Sharon Byrnes
Sarah Cairns-Smith
Geriann Camarro King
Kathleen Cannon
Peter and Nancy Cannon
Marco Capalbo
Thomas J Caruso
Sharon Catania
Susan Cathcart
Jeffrey Cederstrom
Joan Centofanti
Lisa Chavez
Barbara Cheek
Michele Cho
Arnie Civins
Susan Clay
Rodgers Coffing
Stacey Cogswell
Crystal Collingsworth
Kristen Comeau
Sheryl Comenzo
Thomas Connolly
George Cook
Helen Cools-Lartigue
Sharon Coucom Phillips
Frank Courtney
Sally Cox
Cathleen Crane
Dukagjin Creedon
Kathleen Cronin
Cathy Cunningham
Jeannette M. Cuthaw
Michelle Dalton
Kathleen M Daniels
Samantha Davies
Dotti Day
Cedric Degraeuwe
Karen Degroot
Dennis Deperro
Sue Dishaw
Nan Doerr
Mary Jo Dolan
Reva Dolobowsky
Paul Dunn
Alison Dyer
Kevin Eitel
Mick Engle
John Falls
Donald Fazio
Sondra Feher Dc
Jim Festa
Theresa Feyereisen
Pollnow
Sara Fiedler
Mucka Finyardi
Lisa Fisher
Christine Fitzsimmons
Howard Freedman
Joan Freeman
Heidi Funderburk
Jack Gabrielse
M. Gaich
Mr. C J Galleymore
Sabrina Gardner
Deborah Gaw
Heather Geary
Virginia Giffels
Jennifer Gill
Jonathan Goldsmith
Kathryn Gordon
Barbara Gordon
Ian Gosling
Ann Granbery
Eloise Grathwohl
Madison Grefenstette
Christiaan Grove
Laurie Guberman
Mary Ann Guilmette
B Haddon
Elsi Hakim
Maureen Hapach
Matthew Hardman
Karen Harris
Timothy Harrison
Henry Harrison
Luella Hawley
Kyle Healy
Mary Healy
Cynde Heath
Dena Heath
Jay Hebert
Amy Hedison
Jean Hedstrom
David Helman
Mackenzie Heranic
Sharon Hesko Profera
Jane Butler Hines
James Hodgson
Candy Holland-Ward
Jonathan Hoopingarner
Stan Ingersoll
Elyse Irene
Julie Jackson
Karl Jaufmann
Darcie Jester
Rob Jockel
Lisa Jordan
Joanne Kahn
Kim Kaminer
Marie Kashner
Doug Kaye
Florence Kayser
Jeffery Kelly
Jeremy Kidd
Bonnie Kidder
Michael Kidwell
Noelle Kim
Arthur Kinnealey
Holly Kinney
Tom Kneeshaw
Alexa Knight
Kurt Knoblauch
John Kolbisen
Harold Kowalski
Mj Krauter
Rob Kuehn
Demos Kyriacou
John Landefeld
Mike Lane
Sally Larhette
Laurie Larrea
Nancy Lassalle
Virginia Laue
Robert Leach
Jin Lee
Joseph Leffel
Barb Leitch
Adam Leonard
Joel Levin
Bill and Sandy Lewis
Judith Lewis
Jesse Lewis
Nicholas Lish
Brittney Lofthouse
Mark Lofton
Leonard London
Tracy Long
Erica Long
Leslie Lope
Sandra Lousada
Olivia Lousada
Bob & Judy Lowell
Phyllis Lusher
Terri Lustick
Cynthia Lyon
Stephen and Donna Lyons
Annick Ma
Marianne Macdonald
Luis Macias
Mandy MacMahon
Anne Madden
Dottie Malcolm
Janice Maltese
Bernadine Markey
Rachelle Martin
Christina Matsouka
Paraskevi Matsouka
Michele Mazzei
Mike McCarthy
Tom McCarty
Kevin McElroy
George Jody Mcgee
Kate Mcgee
Elizabeth McGiffert
Miranda Mckee
Kerry Mcmahon
Sue McSherry
Ed Meek
Arlene and Abraham Meilich
Gema Mendez
Chip Miller Amyloidosis Foundation
Sarah Reagan Miller
Art Miller
Susan Mills
Kerryann Haase Minton
Kevin Mitchell
Virginia Mogavero
Renee Mohrmann
Cynthia Musallam
Nancy Najim
Megan Nalley
Bethanna Nalley
Elizabeth Negrelli
Barbara Newman
Winnelle Newton
Oliver Nguyen
Judith Nickel
S. O’Brien
Beverly O’connor
Erica Omundsen
Lauri Ortega
Annemarie Pacheco
Thomas Pagel
John Palma
Paul Parfrey
Mrs. Sophie Parsons
Nancy Weir Payne
Anna Peck Herrera
Lidia Penalver
Renée Peoples
Heather Peters
Kay Pfeiffer
Judy and Bruno Pistrin
Angela Pizzi
Michael Polydefkis
Accelerating the development of and access to new and innovative treatments for amyloidosis.

Amyloidosis Research Consortium
320 Nevada Street Suite 210
Newton, MA 02460

E arc@arci.org
T 617.467.5170